Prince, Derek J.
Patel, Deendayal
Kachlany, Scott C.
Funding for this research was provided by:
National Cancer Institute (R41CA173900)
Article History
Received: 12 April 2021
Accepted: 26 August 2021
First Online: 10 September 2021
Competing interests
: S.C.K. declares competing interests in the form of stock ownership in the company (Actinobac Biomed, Inc.) that has licensed the use of leukotoxin. In addition, S.C.K. has received consulting fees from this company. There are no other conflicts of interest to declare.